Cancers risk higher for ladies in discontinued hormone treatment trial slightly A follow-up study of participants in the Women’s Health Initiative clinical trial led by a University of NEW YORK at Chapel Hill researcher has discovered that ladies who were taking the combined hormone therapy of estrogen plus progestin may have an elevated risk of cancer because the intervention was stopped, in comparison to participants in the trial’s placebo group. The study’s lead writer is certainly Dr. Gerardo Heiss, a Kenan professor of epidemiology in the UNC College of Public Wellness . The trial was halted in July 2002 after individuals had been on the therapy for an average of 5.6 years because researchers saw an elevated threat of breast cancer and cardiovascular disease in women randomly assigned to hormone therapy, weighed against those who received a placebo.